Clinical Trial Update: Dexmedetomidine in Modifying Immune Paralysis In Patient With Septic Shock [Phase 2]

View source ↗

Summary

Phase 2 clinical trial examining dexmedetomidine for modifying immune paralysis in patients with septic shock has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Septic Shock

Drugs mentioned

• Dexmedetomidine (Dexmedetomidine)

Snippet

Sponsor: Kasr El Aini Hospital | Conditions: Septic Shock | Phase 2 | Status: COMPLETED